DANAHER CORP /DE/

WASHINGTON, DC · CIK 0000313616 · Medtech · Public

Life sciences instruments, diagnostics hardware, and laboratory equipment platforms

danaher.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$13M
1 Form D · Apr 2018
102 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$12,907,700
Form D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1076ZSX MEDICAL LLC—$1.1M
1077Reflexion Pharmaceuticals, Inc.—$1.1M
1078PathogenDx, Inc.—$675K
1079DANAHER CORP /DE/—$13M
1080Vira Regen Inc.—$3.0M
1081CRESCEL LLC—$1.4M
1082CALYX, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 20 related persons
  • Rainer BlairExecutive Officer
  • Daniel ComasExecutive Officer
  • William Daniel IIExecutive Officer
  • Donald EhrlichDirector
  • Brian EllisExecutive Officer
  • Linda Hefner FillerDirector
  • Thomas Joyce, Jr.Director · Executive Officer
  • William KingExecutive Officer
  • Angela LalorExecutive Officer
  • Teri List-StollDirector
  • Walter Lohr, Jr.Director
  • Robert LutzExecutive Officer
  • Mitchell RalesDirector · Executive Officer
  • Steven RalesDirector · Executive Officer
  • Daniel RaskasExecutive Officer
  • John SchwietersDirector
  • Alan SpoonDirector
  • Raymond Stevens, Ph.D.Director
  • Joakim WeidenmanisExecutive Officer
  • Elias ZerhouniDirector

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.